enGene Holdings Inc. (NASDAQ:ENGN) Stake Cut by BVF Inc. IL

BVF Inc. IL decreased its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 6.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 2,106,037 shares of the company's stock after selling 145,000 shares during the period. BVF Inc. IL owned approximately 4.76% of enGene worth $14,005,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ENGN. Vontobel Holding Ltd. acquired a new stake in shares of enGene in the fourth quarter worth $69,000. Jane Street Group LLC purchased a new position in enGene in the fourth quarter valued at about $93,000. Franklin Resources Inc. lifted its stake in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after purchasing an additional 389,918 shares in the last quarter. Finally, Blue Owl Capital Holdings LP lifted its stake in shares of enGene by 3.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after purchasing an additional 101,006 shares in the last quarter. Hedge funds and other institutional investors own 64.16% of the company's stock.

enGene Stock Down 0.5 %

NASDAQ ENGN traded down $0.02 during trading hours on Wednesday, reaching $3.67. 26,688 shares of the company traded hands, compared to its average volume of 126,621. The stock has a market capitalization of $187.09 million, a PE ratio of -6.33 and a beta of -0.36. The company has a 50 day moving average of $4.55 and a two-hundred day moving average of $6.40. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene Holdings Inc. has a 12 month low of $3.50 and a 12 month high of $15.00.

Analyst Ratings Changes

ENGN has been the topic of several analyst reports. Piper Sandler began coverage on enGene in a report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 target price on the stock. UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. Morgan Stanley decreased their target price on shares of enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price target on shares of enGene in a research note on Tuesday, April 29th. Finally, HC Wainwright reissued a "buy" rating and issued a $25.00 price objective on shares of enGene in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, enGene currently has a consensus rating of "Buy" and a consensus price target of $23.29.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.